How palbociclib/palbociclib treats breast cancer

Palbociclib/ Palbociclib is a targeted therapy drug that helps reduce the growth and spread of cancer cells in the body. Palbociclib is used to treat advanced or metastatic breast cancer in women with HR-positive, HER2-negative breast cancer, often when the cancer progresses or spreads to other parts of the body despite other treatments.

Pabociclib belongs to CDK 4/6 inhibitor class of drugs. CDK4/6 inhibitors, such as palbociclib, target specific enzymes called CDK4 and CDK6. CDK stands for cyclin-dependent kinase, an enzyme important for cell division. By blocking these enzymes, palbociclib slows cell division, allowing new cancer cells to grow.

Some cancers, such as hormone receptor-positive breast cancer, are more likely to have overactive and unregulated CDK4/6 activity, and CDK 4/6 inhibitors (such as palbociclib) are available for treatment.

Research suggests CDK4/6 inhibitors such as palbociclib may extend the time people have before their cancer spreads. More evidence is needed to determine their impact on overall survival.

Palbociclib is usually taken with other drugs such as aromatase inhibitors or fulvestrant for 21 days. This cycle is repeated every 28 days as long as you respond positively to the medication and tolerate the side effects well.

Palbociclib is now available in the domestic market and has also been included in the scope of drugs reimbursed by medical insurance. Taking the common domestic dosage of 125mg*21 tablets as an example, the price after reimbursement by medical insurance is about 4,200 yuan. In addition, let’s also take a look at the situation of palbociclib in overseas markets, which includes original drugs and generic drugs. It should be noted that the price of overseas original drugs is higher than the domestic price after reimbursement, so it is more economical for patients to purchase original drugs directly from the domestic market. On the other hand, overseas generic drugs mainly come from Bangladesh and Laos. The price of palbociclib produced by different pharmaceutical factories in Bangladesh ranges from 780 to 2800 yuan.